Putney Hires Gary Eaton as Vice President of Sales and Marketing

Portland, ME, July 21, 2015 — Putney, Inc., a rapidly growing pet pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has hired Gary Eaton as Vice President of Sales and Marketing, reporting to Jean Hoffman, Putney's President and CEO. As part of Putney's senior management team, Gary will lead the commercial team to deliver revenue growth fueled by rapid adoption of Putney's recent and upcoming product launches. Putney has launched six veterinary generics in the last nine months, including three first-to-market generics:

Putney's Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, generic of Telazol®
Putney's Dexmedetomidine HCl, generic of Dexdomitor®
Putney's Carprofen Chewable Tablets, generic of Rimadyl® Chewable Tablets.
Hoffman calls Eaton an "analytical marketing expert" and says she is impressed by his track record of leadership and sales growth during his long career at Idexx. "Gary understands our sales channels extremely well. He is smart, focused, and trusted by our distribution partners. I am delighted to have Gary leading our commercial team to drive sales of our expanding product portfolio," says Hoffman.

Eaton will leverage his sixteen-year career at Idexx where, in various senior leadership roles, he developed expertise in integrating marketing and selling efforts across distribution, direct sales and field sales teams to defend market share and commercialize new products. "Putney is poised for dramatic growth because we provide a real solution for one of the major problems facing veterinarians and pet owners – the increasing cost of pet ownership. We have a terrific product portfolio that is growing rapidly, we have outstanding support, and we have affordable pricing. Prescribing Putney generics is a simple way for veterinarians to thrive in an economically challenging marketplace," says Eaton.


Telazol® is a registered trademark of Zoetis Services LLC.

Dexdomitor® is a registered trademark of Orion Corporation.

Rimadyl® is a registered trademark of Zoetis Services LLC.

About Putney

Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…